Timothy Coughlin - 07 Jun 2024 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Reporting relationship: Director
Issuer ticker: FATE
Reported as of: 07 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jun 2024, 16:29:36 UTC
Prior SEC filing: 03 Jun 2024
Next SEC filing: 02 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Cindy Tahl, as Attorney-in-Fact

Key filing fact

Timothy Coughlin filed Form 4 for FATE THERAPEUTICS INC (FATE) on 11 Jun 2024.

Key facts

This page summarizes Timothy Coughlin's Form 4 filing for FATE THERAPEUTICS INC (FATE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Jun 2024, 16:29.

Change

Previous filing in this sequence was filed on 03 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FATE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 07 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $3.68
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

Footnote F2

The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.